Roivant Sciences (United States).
company in New York, United States
- Reports this week
- 1
- Active events
- 1
- Connections
- 80
What's happening
Active this week
Earlier this month
-
Eric Venker has been named the CEO of Roivant Sciences Ltd.Some support1 report
-
Roivant Social Ventures made a six-figure legacy donation to No Patient Left Behind.Some support1 report
-
The FCC identified national security concerns involving CITIC subsidiaries, which provided Iran with a $10 billion line of credit.Some support1 report
-
Roivant Sciences and Pharming Group are being compared as healthcare companies that develop medicines in the US and Europe.Some support1 report
One to three months ago
-
Roivant Sciences and Janux Therapeutics are healthcare companies competing for investment.Some support1 report
-
Ramaswamy's financial profile and business interests in Roivant Sciences are being reported amid the Ohio gubernatorial race.Some support2 reports
-
Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.Well supported4 reports1 development inside
-
Acton's political rivals are contrasting her wealth sources, which stem from a company she founded that is generating wealth.Some support2 reports
-
Roivant Sciences licensed a drug from Pfizer for regulatory approval.Some support2 reports
-
Roivant Sciences identifies a potential market for its successful drug candidate in Europe.Some support2 reports
-
A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.Some support3 reports
Gone quiet
No new reports in 90+ days-
Roivant Sciences received rating updates and price targets from Bank of America, Citigroup, and Leerink Partners.Some support1 report
-
Roivant Sciences is seeking FDA decisions regarding its registrational trial for LPP, which is ongoing.Some support2 reports
-
Roivant Sciences stock, traded on Nasdaq, saw UBS lift its position and Goldman Sachs grow its holdings, with transactions disclosed in SEC filings.Some support7 reports
-
Roivant Sciences and Q32 Bio Inc. are two medical companies currently competing for investment.Some support1 report
-
Roivant Sciences received a buy rating and price targets from Jefferies Financial Group.Some support1 report
-
Roivant filed a 10-Q statement with the SEC on August 12, 2025, while its stock was sliding against a marginally down S&P 500.Some support2 reports
-
Roivant reported financial results from Basel, Switzerland, and hosted a conference call in London.Some support1 report
-
Goldman Sachs resumed coverage of Pulmovant, a Roivant subsidiary, with a 'Buy' rating.Some support2 reports
-
Eric Venker sold shares worth $1,145,000 of Roivant Sciences on June 25, 2025.Speculative1 report
-
Ongoing LNP litigation presents legal uncertainties involving Moderna, Roivant Sciences, and Pfizer.Some support2 reports
-
Roivant Sciences acquired Immunovant and established Vants as a focused subsidiary.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Roivant Sciences (United States) this week
News at the entities that move Roivant Sciences (United States) most-
Vivek Ramaswamy StructuralTrump made threats to Ohio voters and Acton, while legal inquiries target his administration amidst the Acton/Ramaswamy campaign.Moves Roivant Sciences (United States)
-
Securities and Exchange Commission StructuralFiling required regarding institutional ownership changes for the JPMorgan Active Developing Markets Equity ETF with the SEC on June 27, 2026.Moves Roivant Sciences (United States)
-
FDA StructuralFDA accepted Axion BioSystems' Letter of Intent (LOI) for a neural assay on November 10, 2026.Moves Roivant Sciences (United States)
-
SEC StructuralArcutis Biotherapeutics, Inc. disclosed an executive stock sale via a filing with the SEC on November 11, 2026.Moves Roivant Sciences (United States)
-
Citigroup TransactionalAmundi increased its stake in Kroger stock and Citigroup issued a price objective on Kroger shares.Moves Roivant Sciences (United States)
-
Stifel TransactionalStifel analysts discussed RILA's market conditions and sales growth, noting that a recent Stifel acquisition aided segment earnings.Moves Roivant Sciences (United States)
Connections
The 20 strongest of 80, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Vivek Ramaswamy Structural
Vivek Ramaswamy founded Roivant Sciences, and the company's performance significantly shapes his personal wealth.
-
Securities and Exchange Commission Structural
Roivant Sciences is subject to regulation and disclosure requirements enforced by the Securities and Exchange Commission.
-
FDA Structural
Roivant Sciences requires formal regulatory review and approval from the FDA for its drug products.
-
Pfizer Transactional
Pfizer and Roivant are engaged in LNP litigation and operate under a formal drug licensing and supply agreement.
-
SEC Structural
Roivant Sciences is subject to formal regulatory oversight by the SEC regarding insider trading disclosures.
-
Citigroup Transactional
Citigroup evaluated Roivant Sciences by raising its target price and issuing a buy rating.
-
Leerink partners Mentioned together
Leerink partners provides financial analysis and price targets for Roivant Sciences.
-
Fifth Third Bancorp Transactional
Fifth Third Bancorp increased its investment position in Roivant Sciences.
Show all 20 connections
-
Jefferies Financial Group Transactional
Jefferies Financial Group provided buy ratings and price targets for Roivant Sciences.
-
Stifel Transactional
Stifel initiated market coverage of Roivant Sciences and assigned a Buy rating.
-
niu Operational
A is involved in a Phase III study conducted by Roivant Sciences (B).
-
CITIC Group Transactional
Roivant subsidiaries received partial financing from CITICPE.
-
MarketBeat Mentioned together
MarketBeat, as a financial information aggregator, reports consensus ratings and target prices for Roivant Sciences.
-
Europe Shared context
Roivant Sciences views Europe as a potential market for its successful drug candidates.
-
LPP Structural
Roivant Sciences is conducting a registrational trial for LPP.
-
Nasdaq Shared context
Roivant Sciences is a company whose stock is listed and traded on the Nasdaq exchange.
-
Bank of America Mentioned together
Bank of America issued a neutral rating regarding Roivant Sciences.
-
TD Cowen Mentioned together
TD Cowen issued buy rating reports regarding Roivant Sciences.
-
Morgan Stanley Transactional
Investment activity between Morgan Stanley and Roivant Sciences, including stake reductions and increases.
-
Pharming Group (Netherlands) Mentioned together
The entities are co-mentioned in the context of being compared healthcare companies.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
5 events- Forbes reported on Vivek Ramaswamy's personal wealth being shaped by his stake in Roivant Sciences.
- Roivant Social Ventures made a six-figure legacy donation to No Patient Left Behind.
- The FCC identified national security concerns involving CITIC subsidiaries, which provided Iran with a $10 billion line of credit.
- Roivant Sciences and Pharming Group are being compared as healthcare companies that develop medicines in the US and Europe.
- Roivant Sciences and Janux Therapeutics are healthcare companies competing for investment.
September 2026
5 events- Ramaswamy's financial profile and business interests in Roivant Sciences are being reported amid the Ohio gubernatorial race.
- Acton's political rivals are contrasting her wealth sources, which stem from a company she founded that is generating wealth.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- Roivant Sciences identifies a potential market for its successful drug candidate in Europe.
- A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.
Show 3 earlier months
August 2026
2 eventsJuly 2026
2 eventsJune 2026
8 events- Analyst firm Leerink partners raised the price target for Roivant based on share count forecast on August 13, 2025.
- Roivant Sciences received a buy rating and price targets from Jefferies Financial Group.
- Roivant filed a 10-Q statement with the SEC on August 12, 2025, while its stock was sliding against a marginally down S&P 500.
- Roivant reported financial results from Basel, Switzerland, and hosted a conference call in London.
- Goldman Sachs resumed coverage of Pulmovant, a Roivant subsidiary, with a 'Buy' rating.
- Eric Venker sold shares worth $1,145,000 of Roivant Sciences on June 25, 2025.
- Ongoing LNP litigation presents legal uncertainties involving Moderna, Roivant Sciences, and Pfizer.
- Roivant Sciences acquired Immunovant and established Vants as a focused subsidiary.